Participation of the neutrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2182-2190

  Faleiros Tamashiro, Leticia ^a   Oliveira, Renê D R ^a   Oliveira, Rodrigo ^a   Comini Frota, Elizabeth Regina ^b   Donadi, Eduardo Antonio ^a   Del Ben, Cristina Marta ^a   Teixeira, Antonio Lucio ^b   Louzada Junior, Paulo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Brain derived neurotrophic factor; Lupus; Neuropsychiatric; SLEDAI

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; PREDNISONE; BIOLOGICAL MARKER; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CENTRAL NERVOUS SYSTEM AGENTS;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; EVALUATION STUDY; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; BLOOD; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84925222263     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu251     Document Type: Article

References (47)

1. American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42: 599–608.
2. Sciascia S, Bertolaccini ML, Baldovino S et al. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev 2013;12:426–9.
3. Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol 2011;9:449–57.
4. Sato S, Kawashima H, Hoshika A, Yoshio T. Clinical analysis of anti-NR2 glutamate receptor antibodies and interleukin-6 with neuropsychiatric systemic lupus erythematosus. Rheumatology 2011;50:2142–4.
5. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36:297–315.
6. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology 2008;47:1498–502.
7. Bonfa E, Golombek SJ, Kaufman LD et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265–71.
8. Govoni M, Bombardieri S, Bortoluzzi A et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology 2012;51:157–68.
9. Leibrock J, Lottspeich F, Hohn A et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989;341:149–52.
10. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997;52:883–94.
11. Reichardt LF. Neurotrophin-regulated signal pathways. Philos Trans R Soc Lond B Biol Sci 2006;361:1545–64.
12. Maroder M, Bellavia D, Meco D et al. Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol 1996;157:2864–72.
13. Kruse N, Cetin S, Chan A, Gold R, Luhder F. Differential expression of BDNF mRNA splice variants in mouse brain and immune cells. J Neuroimmunol 2007;182:13–21.
14. Kerschensteiner M, Gallmeier E, Behrens L et al. Activated human T cells, B cells, and monocytes produce brain derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865–70.
15. Braun A, Lommatzsch M, Mannsfeldt A et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999;21:537–46.
16. Moalem G, Leibowitz-Amit R, Yoles E et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49–55.
17. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003;53:292–304.
18. Frota ER, Rodrigues DH, Donadi EA et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009, 28;460:130–2.
19. Fauchais AL, Lise MC, Marget P et al. Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study. PLoS One 2013;8: e79414.
20. Ikenouchi A, Yoshimura R, Ikemura N et al. Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1359–63.
21. Ikenouchi-Sugita A, Yoshimura R et al. Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes. Neuropsychiatr Dis Treat 2008;4:1277–81.
22. Ikenouchi-Sugita A, Yoshimura R, Okamoto T et al. Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. World J Biol Psychiatry 2010;11:121–8.
23. Petri M, Orbai AM, Alarcón GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
24. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:685–708.
25. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
26. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV). Washington, DC: Amercian Psychiatric Press, 1996.
27. Del-Ben C, Vilela J, Crippa J et al. Confiabilidade Teste-Reteste da Entrevista Clínica Estruturada para o DSM-IV – Versão Clínica (SCID-CV) Traduzida para o Português. Rev Bras Psiquiatr 2001;23:156–9.
28. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain derived neurotrophic factor in brain and rat but not
29. mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996;709:122–30.
30. Fujimura H, Altar CA, Chen R et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonistic stimulation. Thromb Haemost 2002;87:728–34.
31. Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 2010; 4:871–87.
32. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immune reactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260–5.
33. Telerman A, Lapter S, Sharabi A, Zinger H, Mozes E. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations. J Neuroimmunol 2011;232:151–7.
34. Hattori A, Tanaka E, Murase K et al. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J Biol Chem 1993;268:2577–82.
35. Torcia M, Bracci-Laudiero L, Lucibello M et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996;85:345–56.
36. Thorpe LW, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on the expression of interleukin-2 receptors on cultured human lymphocytes. Ann N Y Acad Sci 1987;496:310–11.
37. Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69: 2074–82.
38. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005;31:273–98.
39. Shimizu E, Hashimoto K, Olamura N et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–5.
40. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11: 1169–80.
41. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527–32.
42. Onen Sertoz O, Tolga Binbay I, Koylu E et al. The role of BDNF and HPA axis in the neurobiology of burnout syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1459–65.
43. Tamaji A, Iwamoto K, Kawamura Y et al. Differential effects of diazepam, tandospirone, and paroxetine on plasma brain-derived neurotrophic factor level under mental stress. Hum Psychopharmacol 2012;27:329–33.
44. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011;24:122–7.
45. Schaaf MJ, De Kloet ER, Vreugdenhil E. Corticosterone effects on BDNF expression in the hippocampus. Implications for memory formation. Stress 2000; 3:201–8.
46. Jacobsen JP, Mørk A. Chronic corticosterone decreases brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex of the rat. Brain Res 2006;1110:221–5.
47. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009;14:51–9.